ClinicalTrials.gg
TerminatedNCT00626548ENTHUSE M0Updated Sep 3, 2012Results posted

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer

A Phase 3 interventional study of ZD4054 and Palcebo in Prostate Cancer, sponsored by AstraZeneca. Terminated at 330 sites in 39 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-09-03.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Why this study was terminated
early efficacy review by the Independent Data Monitoring Committee indicated it was unlikely to meet its primary efficacy endpoints

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,577
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 91 studies in Prostatic Neoplasms by AstraZeneca — 15 open to participants now, 29 under way, 8 of them phase 3. Prostatic Neoplasms · AstraZeneca.

Enrollment
3rd of 60
2,577 · median 110
Started
2008
with 4 others
Phase 3
17 of 91
3 open now
Registered
18th of 91
by date

Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 3rd largest by enrollment of the 60 interventional ones that give a count, is one of 5 that started in 2008, is one of 17 in phase 3, and was the 18th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 91 studies in Prostatic Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Prostatic Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

Enthuse M0 is a large phase III clinical trial studying the efficacy of ZD4054 (Zibotentan) in hormone resistant prostate cancer (HRPC).

This clinical trial will test if the Endothelin A Receptor Antagonist ZD4054 (Zibotentan) can improve progression-free survival and overall survival against a background of existing prostate cancer treatments.

ZD4054 (Zibotentan) is a new type of agent, which is thought to slow tumour growth and spread by blocking Endothelin receptor activity. This trial will look at the effects of ZD4054 (Zibotentan) in hormone resistant prostate cancer (HRPC) patients who have had rising PSA after surgical or medical castration but have no evidence of metastases.

All patients participating in this clinical trial will receive existing prostate cancer treatments in addition to trial therapy.

Half the patients will receive ZD4054 (Zibotentan) , and half the patients will receive placebo in addition to standard prostate cancer therapy. By participating in this trial there is a 50% chance that patients will receive an agent that may slow the progression of the tumour.

No patients will be deprived of standard prostate cancer therapy.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Hormone Resistant Prostate Cancer
  • Endothelin A Receptor Antagonist
  • Endothelin A
  • Endothelin A antagonist
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients who answer TRUE to the following criteria may be eligible to participate in this study.

  • Confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate) that has NOT spread to the other parts of the body (). Patients with lymph node involvement may be eligible if specified criteria is met.
  • Increasing Prostate Specific Antigen (PSA), collected within one year of enrollment
  • Currently receiving treatment with surgical or medical castration

Exclusion criteria

Exclusion Criteria:

Patients who answer TRUE to the following may NOT be eligible to participate in this study.

  • Currently using opiate based pain killers for cancer related pain
  • Previous treatment with chemotherapy (paclitaxel, docetaxel, and mitoxantrone). Prior targeted cancer therapies are permitted if received during a previous clinical trial
  • Suffering from heart failure or had a myocardial infarction within last 6 months
  • A history of epilepsy or seizures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
2,577 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching Placebo

    Drug: Palcebo

  • Experimental
    ZD4054

    ZD4054 (Zibotentan)

    Drug: ZD4054

Interventions

  • DrugZD4054

    10 mg once daily oral dose

    Also known as: Zibotentan

  • DrugPalcebo

    Matching Plcebo oral tablet once daily

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Number of participants who have died at early analysis data cut off (DCO)

    Time frame: From date of randomization until date of death, assessed up to 33 months

  2. Progression Free Survival

    Number of participants who have a progression event at the early analysis DCO, where progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline

    Time frame: Participants were followed up for progression every 4 weeks for the first 16 weeks then every 16 weeks

Secondary outcomes

  1. Health Related Quality of Life

    Time frame: Participants were followed up every 4 weeks for the first 16 weeks then every 16 weeks

  2. Time to Prostate-specific Antigen (PSA) Progression

    Time frame: Participants were followed up every 4 weeks for the first 16 weeks then every 16 weeks

  3. Time to Symptomatic Progression

    Time frame: Participants were followed up every 4 weeks for the first 16 weeks then every 16 weeks

07

Results

Posted Jun 1, 2012

Participant flow

2577 patients with hormone-resistant prostate cancer patients and bone metastasis were recruited between 15th January 2008 and 3rd May 2011

Participant flow — Overall Study
MilestoneZD4054Placebo
Started705716
Patients received treatment703712
Completed00
Not completed705716
Withdrew: Adverse event16444
Withdrew: Withdrawal by subject4246
Withdrew: Protocol violation411
Withdrew: Lost to follow-up22
Withdrew: Other termination reason493613

Outcome measures

PrimaryOverall Survival

Number of participants who have died at early analysis data cut off (DCO)

Time frame:
From date of randomization until date of death, assessed up to 33 months
Reported as:
Number · Participants
Overall Survival
ParticipantsZD4054Placebo
Overall Survival4039
PrimaryProgression Free Survival

Number of participants who have a progression event at the early analysis DCO, where progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline

Time frame:
Participants were followed up for progression every 4 weeks for the first 16 weeks then every 16 weeks
Reported as:
Number · Participants
Progression Free Survival
ParticipantsZD4054Placebo
Progression Free Survival131162
SecondaryHealth Related Quality of Life
Time frame:
Participants were followed up every 4 weeks for the first 16 weeks then every 16 weeks

Results for this outcome have not been posted.

SecondaryTime to Prostate-specific Antigen (PSA) Progression
Time frame:
Participants were followed up every 4 weeks for the first 16 weeks then every 16 weeks

Results for this outcome have not been posted.

SecondaryTime to Symptomatic Progression
Time frame:
Participants were followed up every 4 weeks for the first 16 weeks then every 16 weeks

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ZD4054—148/703 (21.1%)531/703 (75.5%)
Placebo—138/712 (19.4%)392/712 (55.1%)
Most frequent serious events
Showing 10 of 219
Most frequent serious events
EventZD4054Placebo
Cardiac FailureCardiac disorders9/7033/712
PneumoniaInfections and infestations7/7035/712
Angina PectorisCardiac disorders1/7037/712
HydronephrosisRenal and urinary disorders1/7037/712
Myocardial InfarctionCardiac disorders5/7033/712
Renal Failure AcuteRenal and urinary disorders5/7032/712
Gastric CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/7035/712
Atrial FibrillationCardiac disorders4/7032/712
Oedema PeripheralGeneral disorders4/7030/712
Basal Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/7031/712
Most frequent other events
Showing 10 of 20
Most frequent other events
EventZD4054Placebo
Oedema PeripheralGeneral disorders268/70388/712
HeadacheNervous system disorders188/70382/712
Nasal CongestionRespiratory, thoracic and mediastinal disorders176/70339/712
FatigueGeneral disorders71/70379/712
ConstipationGastrointestinal disorders64/70376/712
DiarrhoeaGastrointestinal disorders46/70363/712
NauseaGastrointestinal disorders59/70361/712
RhinitisInfections and infestations56/70317/712
Urinary Tract InfectionInfections and infestations43/70354/712
ArthralgiaMusculoskeletal and connective tissue disorders40/70354/712

Baseline characteristics

Age Continuous
Age Continuous(years)ZD4054PlaceboTotal
Overall72.4 ± 7.872.5 ± 7.872.45 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)ZD4054PlaceboTotal
Female000
Male7057161421
08

Study locations

330 sites
  • Research Site
    Tucson, Arizona, United States
  • Research Site
    Greenbrae, California, United States
  • Research Site
    Los Angeles, California, United States
  • Research Site
    San Diego, California, United States
  • Research Site
    San Francisco, California, United States
  • Research Site
    Denver, Colorado, United States
  • Research Site
    Norwich, Connecticut, United States
  • Research Site
    Washington, District of Columbia, United States
  • Research Site
    Boca Raton, Florida, United States
  • Research Site
    Miami, Florida, United States
  • Research Site
    Ocala, Florida, United States
  • Research Site
    Port St. Lucie, Florida, United States
  • Research Site
    Atlanta, Georgia, United States
  • Research Site
    Macon, Georgia, United States
  • Research Site
    Kansas City, Kansas, United States
  • Research Site
    New Orleans, Louisiana, United States
  • Research Site
    Baltimore, Maryland, United States
  • Research Site
    Rockville, Maryland, United States
  • Research Site
    Minneapolis, Minnesota, United States
  • Research Site
    Lincoln, Nebraska, United States
  • Research Site
    Las Vegas, Nevada, United States
  • Research Site
    Brooklyn, New York, United States
  • Research Site
    Chapel Hill, North Carolina, United States
  • Research Site
    Bismarck, North Dakota, United States
  • Research Site
    Canton, Ohio, United States
  • Research Site
    Cincinnati, Ohio, United States
  • Research Site
    Philadelphia, Pennsylvania, United States
  • Research Site
    Pittsburgh, Pennsylvania, United States
  • Research Site
    Charleston, South Carolina, United States
  • Research Site
    Mystle Beach, South Carolina, United States
  • Research Site
    Raleigh, South Carolina, United States
  • Research Site
    Memphis, Tennessee, United States
  • Research Site
    Nashville, Tennessee, United States
  • Research Site
    San Antonio, Texas, United States
  • Research Site
    Burlington, Vermont, United States
  • Research Site
    Seattle, Washington, United States
  • Research Site
    Wenatchee, Washington, United States
  • Research Site
    Milwaukee, Wisconsin, United States
  • Research Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
  • Research Site
    Rosario, Santa Fe, Argentina
  • Research Site
    Santa Fe, Argentina
  • Research Site
    Darlinghurst, New South Wales, Australia
  • Research Site
    Hornsby, New South Wales, Australia
  • Research Site
    Westmead, New South Wales, Australia
  • Research Site
    Wollongong, New South Wales, Australia
  • Research Site
    Wodonga, Victoria, Australia
  • Research Site
    Nedlands, Western Australia, Australia
  • Research Site
    Sydney, Australia
  • Research Site
    Graz, Austria
  • Research Site
    Innsbruck, Austria
  • Research Site
    Wels, Austria
  • Research Site
    (Wilrijk) Antwerpen, Belgium
  • Research Site
    Brussels, Belgium
  • Research Site
    Edegem, Belgium
  • Research Site
    Gent, Belgium
  • Research Site
    Kortrijk, Belgium
  • Research Site
    Leuven, Belgium
  • Research Site
    Liege, Belgium
  • Research Site
    Goiania, Goias, Brazil
  • Research Site
    Belo Horizonte, Minas Gerais, Brazil
  • Research Site
    Curitiba, Parana, Brazil
  • Research Site
    Londrina, PR, Brazil
  • Research Site
    Porto Alegre, Rio Grande do Sul, Brazil
  • Research Site
    Rio de Janeiro, RJ, Brazil
  • Research Site
    Santo Andre, Sao Paulo, Brazil
  • Research Site
    Sao Paulo, Brazil
  • Research Site
    Calgary, Alberta, Canada
  • Research Site
    Edmonton, Alberta, Canada
  • Research Site
    Vancouver, British Columbia, Canada
  • Research Site
    Victoria, British Columbia, Canada
  • Research Site
    Winnipeg, Manitoba, Canada
  • Research Site
    Burlington, Ontario, Canada
  • Research Site
    Hamilton, Ontario, Canada
  • Research Site
    Kingston, Ontario, Canada
  • Research Site
    Kitchener, Ontario, Canada
  • Research Site
    London, Ontario, Canada
  • Research Site
    North York, Ontario, Canada
  • Research Site
    Oakville, Ontario, Canada
  • Research Site
    Toronto, Ontario, Canada
  • Research Site
    Greenfeild Park, Quebec, Canada
  • Research Site
    Montreal, Quebec, Canada
  • Research Site
    Point-Claire, Quebec, Canada
  • Research Site
    Quebec City, Quebec, Canada
  • Research Site
    Sherbrooke, Quebec, Canada
  • Research Site
    La Serena, Chile
  • Research Site
    Santiago, Chile
  • Research Site
    Temuco, Chile
  • Research Site
    Vina del Mar, Chile
  • Research Site
    Nanjing, Jiangsu, China
  • Research Site
    Hangzhou, Zhejiang, China
  • Research Site
    Beijing, China
  • Research Site
    Chongqing, China
  • Research Site
    Guangzhou City, China
  • Research Site
    Hubei, China
  • Research Site
    Jiangsu, China
  • Research Site
    Shanghai, China
  • Research Site
    Shanxi, China
  • Research Site
    Tianjin, China
  • Research Site
    Zejiang, China
  • Research Site
    Bogota, Colombia

Showing the first 100 of 330 sites across 39 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Jan 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2012, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2008
First posted
Feb 29, 2008
Start
Jan 2008
Primary completionActual
Jan 2011
CompletionActual
May 2011
Results first posted
Jun 1, 2012
Last update
Sep 3, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00626548
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 29, 2008
Start date
Jan 2008
Primary completion
Jan 2011
Completion
May 2011
Results posted
Jun 1, 2012
Last update
Sep 3, 2012

Study contacts

Kurt Miller, Prof., M.D.
principal investigator · Charite University, Berlin, Germany
Tia Higano, MD
principal investigator · University of Washington

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZD4054

Start the discussion